Nima Farzan named CEO of Latigo

Nima Farzan became CEO of non-opioid analgesics company  Latigo Biotherapeutics Inc., which is developing Nav1.8-targeting small molecules. Farzan, who succeeds Westlake Village Biopartners’ Desmond Padhi, was most recently CEO of Kinnate Biopharma Inc., which was acquired by Xoma Corp. (NASDAQ:XOMA).

Zhou Hua resigned as CFO of  Walvax Biotechnology Co. Ltd. (SZSE:300142), but will continue to oversee work related to sustainable development and standardized operations. Wu Changxiong, a manager in Walvax’s financial management department and director of its financial management center, was named the new CFO. Run Jiang resigned as the company’s president earlier this month. ...